Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS Ⅱ [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of intracerebroventricular GC1123 in patients with Mucopo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucopolysaccharidosis Type Ii

Drugs mentioned

• GC1123

Snippet

Sponsor: GC Biopharma Corp | Conditions: Mucopolysaccharidosis II, Hunter Syndrome | Phase 1 | Status: ACTIVE_NOT_RECRUITING